Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Clin Cancer Res. 2009 Jul 28;15(15):4875–4884. doi: 10.1158/1078-0432.CCR-09-0110

Figure 1.

Figure 1

RFA and huKS-IL2 IC synergize in induction of antitumor effects. A, Groups of Balb/c mice (7–8 mice per group) were implanted with 5 × 105 CT26-KS tumor cells s.c. on the abdomen on day 0. Mice were treated with partial RFA (25 seconds, day 11), huKS-IL2 (15 μg, days 11–15), or both RFA and huKS-IL2 IC. Untreated tumor-bearing mice served as controls. Data shown are mean tumor volume ± SEM. B, RFA and huKS-IL2 IC therapy prolongs survival of mice. Balb/c mice bearing CT26-KS tumors were treated as described above and followed until euthanasia due to large tumor size was required. Results in A and B are representative of 3 similar experiments. C, Groups of Balb/c mice (n = 8 mice per group) were implanted with CT26-KS tumors as above and treated with partial RFA alone, RFA and 15 μg huKS-IL2 IC on days 10–14, or RFA and 37.5 μg huKS-IL2 IC on days 10 and 14. Data shown are mean tumor volume ± SEM.